ReviewCurrent opinion in biotechnology2014
Application of TALEs, CRISPR/Cas and sRNAs as trans-acting regulators in prokaryotes.
Review in Current opinion in biotechnology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 36 citations in OpenAlex.
- An ATMT-CRISPR/Cas9 system for genome editing in Monascus purpureus.World journal of microbiology & biotechnology · 2026Article
- Guide RNA structure design enables combinatorial CRISPRa programs for biosynthetic profiling.Nature communications · 2024Article
- CRISPR/Cas9-Based Genome Editing and Its Application inJournal of fungi (Basel, Switzerland) · 2022Review
- Carrier strategies boost the application of CRISPR/Cas system in gene therapy.Exploration (Beijing, China) · 2022Review
- Efficient genome editing in filamentous fungi via an improved CRISPR-Cas9 ribonucleoprotein method facilitated by chemical reagents.Microbial biotechnology · 2021Article
- Post-Transcriptional Control in the Regulation of Polyhydroxyalkanoates Synthesis.Life (Basel, Switzerland) · 2021Review
- Converting a Periplasmic Binding Protein into a Synthetic Biosensing Switch through Domain Insertion.BioMed research international · 2019Review
- Protein Engineering Strategies to Expand CRISPR-Cas9 Applications.International journal of genomics · 2018Review
- Transcription control engineering and applications in synthetic biology.Synthetic and systems biotechnology · 2017Review
- CRISPR interference as a titratable, trans-acting regulatory tool for metabolic engineering in the cyanobacterium Synechococcus sp. strain PCC 7002.Metabolic engineering · 2016Article
- Extending CRISPR-Cas9 Technology from Genome Editing to Transcriptional Engineering in the Genus Clostridium.Applied and environmental microbiology · 2016Article
- CRISPR-on system for the activation of the endogenous human INS gene.Gene therapy · 2016Article
- A transcription activator-like effector (TALE) induction system mediated by proteolysis.Nature chemical biology · 2016Article
- Programmable control of bacterial gene expression with the combined CRISPR and antisense RNA system.Nucleic acids research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The last several years have witnessed an explosion in the understanding and use of novel, versatile trans-acting elements. TALEs, CRISPR/Cas, and sRNAs can be easily fashioned to bind any specific sequence of DNA (TALEs, CRISPR/Cas) or RNA (sRNAs) because of the simple rules governing their interactions with nucleic acids. This unique property enables these tools to repress the expression of genes at the transcriptional or post-transcriptional levels, respectively, without prior manipulation of cis-acting and/or chromosomal target DNA sequences. These tools are now being harnessed by synthetic biologists, particularly those in the eukaryotic community, for genome-wide regulation, editing, or epigenetic studies. Here we discuss the exciting opportunities for using TALEs, CRISPR/Cas, and sRNAs as synthetic trans-acting regulators in prokaryotes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.